▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 30, 2024

Bio

Biopharmaceutical stock owners make big gains

  • PUBLISHED :January 28, 2018 - 13:57
  • UPDATED :January 28, 2018 - 13:57
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Stock values for stakeowners of pharmaceutical and biotech firms nearly doubled over the past year, industry data showed on Jan. 28.

A total of 32 people each owned more than 100 billion won (US$93.76 million) worth of shares in biopharmaceutical firms as of Jan. 26‘s closing, according to Chaebul.com. Their stock values have risen 99.4 percent since Jan. 2 last year.




Leading the pack is Celltrion chairman Seo Jung-jin, who claimed 6 trillion won in shares after the stock price of Celltrion Healthcare jumped following its listing in July. Seo owns 36.18 percent of the company stocks but none in Celltrion.

Celltrion Healthcare ranked second in market cap immediately after its listing due to its achievements in overseas markets with biosimilar products. Its current stock price goes for over 120,000 won, nearly triple the starting price of 41,000 won at the time of its listing. Lim Sung-ki of Hanmi Pharm came in second with stocks valued at 2.3 trillion won, up from 1.14 trillion won on Jan. 2 last year. Im owns 34.23 percent of Hanmi Science, the biggest shareholder of Hanmi Pharm.

Lim was followed by Yang Yong-jin, CEO of Komipharm International, whose stocks in the firm were valued at 670 billion won. He holds 29.52 percent of the company stocks, which gained 21.9 percent during the measured period.

Jung Hyun-ho of Medytox came in fourth with 636.1 billion won, an increase of 76.8 percent. Chung Yong-ji of Caregen placed fifth with stocks that rose 20.1 percent to be valued at 628.8 billion won.

By Park Han-na and news wires (hnpark@heraldcorp.com)

EDITOR'S PICKS